friend
I also want to provide clarity on what Hemopurifier® studies have been conducted specific to the Ebola virus.  On October 17th, 2007, Dr. Laura Barrientos at the United States (US) Centers for Disease Control and Prevention (CDC), published a report entitled: \"The Aethlon Hemopurifier®, A Novel Strategy to Address   Ebola and Marburg Haemorrhagic Fevers.\"
The report discussed the potential of the Aethlon Hemopurifier® as a treatment countermeasure against Ebola and other filoviruses.  An excerpt from the report follows:  \"The Hemopurifier® is an extracorporeal device which converges hollow-fiber filtration technology with immobilized affinity agents to allow for the rapid physical removal of virus and soluble viral glycoproteins from the blood. The device basically mimics the natural immune response for clearance of circulating virus and viral toxins. Initial collaborative efforts between the CDC and Aethlon Medical have demonstrated rapid clearance of viral particles from cell culture supernatants (t1/2 20-120 min). The Hemopurifier® was also effective in removing soluble viral glycoproteins (t1/2 30 min). This knowledge represents the basis to further investigate in vivo the potential of the Hemopurifier® as a fast-acting post-exposure intervention to delay disease progression and, possibly, to improve survival. The data resulting from the CDC-Aethlon collaboration has led to further studies through a collaborative research and development agreement with the United States Army Medical Research Institute for Infectious Diseases (USAMRIID).\" The full report can be accessed online at: http://www.aethlonmedical.com/assets/001/5017.pdf
In a follow-on disclosure, we reported that the USAMRIID studies documented that the Hemopurifier® captured approximately 50% of both wild type and mutant strains of ZEBOV (Zaire strain of Ebola) from fluids during one hour in vitro studies. ZEBOV has the highest virus case-fatality rate, up to 90% in some epidemics, with an average case fatality rate of approximately 83% over the previous 27 years. USAMRIID, serves as the lead laboratory for the U.S. Medical Biological Defense Research Program, and plays a key role in national defense and in infectious disease research. USAMRIID operates the only laboratory in the Department of Defense (DOD) equipped to study Ebola and other highly hazardous infectious agents requiring maximum containment at bio-safety level four (BSL-4).